부산대학교 도서관

Peptide receptor radionuclide therapy (PRRT) has become an established treatment for patients with inoperable and/ormetastatic, well-differentiated neuroendocrine tumors with overexpression of somatostatin receptor type 2 (SSTR-2). Thepost-therapy 177Lu-DOTATATE whole-body scan not only assesses the biodistribution of the lesions seen on pre-therapy68 Ga-SSTR PET/CT scan but also provides a quick assessment of disease status and dosimetry during treatment. Like anyother radionuclide scan, the whole-body 177Lu-DOTATATE scan may also show abnormal radiotracer uptake, which mayrequire further imaging to establish its exact etiology. Though radiotracer emboli mimicking focal pulmonary lesions havebeen described with 18F-FDG and 68 Ga-DOTANOC PET/CT scans, similar artifacts with post-therapy 177Lu-DOTATATEscans have not been described. Herein, we report two cases of hot emboli in the post-therapy 177Lu-DOTATATE scans.